Loading
A phase 3 trial of Sacituzumab tirumotecan, Pemetrexed, Tisotumab vedotin in cervical cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) is a phase 3 interventional study registered as NCT06459180 by Merck Sharp & Dohme LLC, with 686 participants planned, started 2024-07-24 and due to reach its primary completion in 2028-06-15. Interventions recorded: Sacituzumab Tirumotecan, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine. Conditions listed: Cervical Cancer. No results are recorded here; the registry entry is the source.
Shares Sacituzumab tirumotecan, Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Recurrent or metastatic cervical cancer, Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Sacituzumab tirumotecan, Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Gemcitabine.
Shares Recurrent or metastatic cervical cancer, Topoisomerase-I inhibitors (and ADC payloads), Cervical cancer, Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).